MA27183A1 - OXO-AZABICYCLIC COMPOUNDS - Google Patents
OXO-AZABICYCLIC COMPOUNDSInfo
- Publication number
- MA27183A1 MA27183A1 MA27842A MA27842A MA27183A1 MA 27183 A1 MA27183 A1 MA 27183A1 MA 27842 A MA27842 A MA 27842A MA 27842 A MA27842 A MA 27842A MA 27183 A1 MA27183 A1 MA 27183A1
- Authority
- MA
- Morocco
- Prior art keywords
- group
- atom
- description
- chosen
- inclusive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
DEPOSANT Société dite: WARNER-LAMBERT COMPANY LLC REVENDICATION DE PRIORITES WO 8 Mars 2002 PCT/EP02/03240 Voir en annexe le titre de l'invention et le texte de l'abrégé Composés oxo-azabicycliques Un composé choisi parmi ceux de formule (I) dans laquelle : X1, X2 et X3 représentent des atomes de N ou des groupes -CR3 dans lesquels R3 est tel que défini dans la description, G1 représente un groupe choisi parmi ceux de formules (i/a) et (i/b) dans lesquelles R4, R5 et R6 sont tels que définis dans la description, G2 représenté un groupe choisi entre une triple liaison carbone-carbone, un groupe -CH=C=CH-, un groupe C=O, un groupe C=S, un groupe S(O)n1 dans lequel n1 représente un nombre entier de 0 à 2 inclus, ou un groupe de formule (i/c) dans laquelle Y1 représente un atome de O, un atome de S, un groupe -NH ou un groupe -N-alkyle, et Y2 représente un atome de O, un atome de S, un groupe -NH, ou un groupe -N-alkyle, n représente un nombre entier de 0 à 6 inclus et m représente un nombre entier de 0 à 7 inclus, Z1 représente un groupe -CR9R10, dans lequel R9 et R10 sont tels que définis dans la description, A représente un système cyclique, R1 représente un groupe choisi entre H, des groupes alkyle, alcényle et alcynyle facultativement substitués et le groupe de formule (i/d) dans laquelle p, Z2, B, q et G3 sont tels que définis dans la description et, facultativement, ses isomères optiques, son N-oxyde et ses sels d'addition formés avec un acide ou une base pharmaceutiquement acceptable, et des produits médicamenteux le contenant sont utiles comme inhibiteurs spécifiques de la métalloprotéase de matrice de type 13.APPLICANT So-called company: WARNER-LAMBERT COMPANY LLC PRIORITY CLAIM WO 8 March 2002 PCT / EP02 / 03240 See in the appendix the title of the invention and the text of the abstract Oxo-azabicyclic compounds A compound chosen from those of formula (I ) in which: X1, X2 and X3 represent atoms of N or groups -CR3 in which R3 is as defined in the description, G1 represents a group chosen from those of formulas (i / a) and (i / b) in which R4, R5 and R6 are as defined in the description, G2 represents a group chosen from a carbon-carbon triple bond, a group -CH = C = CH-, a group C = O, a group C = S, a group S (O) n1 in which n1 represents an integer from 0 to 2 inclusive, or a group of formula (i / c) in which Y1 represents an atom of O, an atom of S, a group -NH or a -N-alkyl group, and Y2 represents an atom of O, an atom of S, a group -NH, or a group -N-alkyl, n represents an integer from 0 to 6 inclusive and m represents an integer from 0 to 7 inclusive, Z1 represents a group -CR9R10, in which R9 and R10 are as defined in the description, A represents a ring system, R1 represents a group chosen from H, alkyl, alkenyl and optionally substituted alkynyl and the group of formula (i / d) in which p, Z2, B, q and G3 are as defined in the description and, optionally, its optical isomers, its N-oxide and its addition salts formed with a pharmaceutically acceptable acid or base, and drug products containing it are useful as specific inhibitors of matrix metalloprotease type 13.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2002/003240 WO2003076416A1 (en) | 2002-03-08 | 2002-03-08 | Oxo azabicyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27183A1 true MA27183A1 (en) | 2005-01-03 |
Family
ID=27798761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA27842A MA27183A1 (en) | 2002-03-08 | 2004-08-31 | OXO-AZABICYCLIC COMPOUNDS |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1492775A2 (en) |
| JP (1) | JP2005526070A (en) |
| KR (1) | KR20040095270A (en) |
| CN (1) | CN1738806A (en) |
| AP (1) | AP2004003125A0 (en) |
| AR (1) | AR039562A1 (en) |
| AU (2) | AU2002249275A1 (en) |
| BR (1) | BR0308280A (en) |
| CA (1) | CA2478706A1 (en) |
| CO (1) | CO5601020A2 (en) |
| EA (1) | EA200401053A1 (en) |
| EC (1) | ECSP045278A (en) |
| IL (1) | IL163818A0 (en) |
| IS (1) | IS7414A (en) |
| MA (1) | MA27183A1 (en) |
| MX (1) | MXPA04008681A (en) |
| NO (1) | NO20044041L (en) |
| OA (1) | OA12782A (en) |
| PA (1) | PA8568501A1 (en) |
| PE (1) | PE20031018A1 (en) |
| PL (1) | PL372622A1 (en) |
| SV (1) | SV2003001495A (en) |
| TN (1) | TNSN04169A1 (en) |
| UY (1) | UY27700A1 (en) |
| WO (2) | WO2003076416A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8539501A1 (en) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | TRIAZOLO COMPOUNDS AS MMP INHIBITORS |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| CA2495293A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
| PA8578101A1 (en) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | HETEROBIARILO DERIVATIVES AS METALOPROTEINASE IN MATRIX INHIBITORS |
| WO2004014384A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
| WO2004014375A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
| CA2497656A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors |
| EP1537098A1 (en) | 2002-08-13 | 2005-06-08 | Warner-Lambert Company LLC | Monocyclic derivatives as matrix metalloproteinase inhibitors |
| WO2004014880A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Chromone derivatives as matrix metalloproteinase inhibitors |
| AU2003253186A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| WO2004014923A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
| WO2004014378A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
| DE10360835A1 (en) * | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New bicyclic imidazole derivatives are dipeptidylpeptidase-IV inhibitors useful to treat e.g. arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis |
| ZA200609259B (en) * | 2004-04-30 | 2008-07-30 | Takeda Pharmaceutical | Heterocyclic amide compound and use thereof as an mmp-13 inhibitor |
| KR20070028536A (en) * | 2004-06-15 | 2007-03-12 | 아스트라제네카 아베 | Substituted quinazolones as anti-cancer agents |
| WO2008043087A2 (en) | 2006-10-05 | 2008-04-10 | Cv Therapeutics, Inc. | Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors |
| WO2012052451A1 (en) | 2010-10-18 | 2012-04-26 | Merz Pharma Gmbh & Co. Kgaa | Metabotropic glutamate receptor modulators |
| CN103524431B (en) * | 2013-09-24 | 2016-01-13 | 西安交通大学 | 3-benzyl-4-quianzolinones and synthetic method thereof and application |
| JO3512B1 (en) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as fgfr kinase modulators |
| LT3353164T (en) | 2015-09-23 | 2022-01-25 | Janssen Pharmaceutica, N.V. | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| JP6898919B2 (en) | 2015-09-23 | 2021-07-07 | ヤンセン ファーマシューティカ エヌ．ベー． | New compound |
| FR3046793B1 (en) * | 2016-01-14 | 2018-01-05 | Les Laboratoires Servier | NOVEL PHOSPHINAN DERIVATIVES AND AZAPHOSPHINANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002513394A (en) * | 1996-12-17 | 2002-05-08 | イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー | Fungicidal quinazolinones |
| PA8539401A1 (en) * | 2001-02-14 | 2002-10-28 | Warner Lambert Co | QUINAZOLINAS AS INHIBITORS OF MMP-13 |
| PA8539301A1 (en) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | INHIBITORS OF THE METALOPROTEINASE OF THE MATRIX |
-
2002
- 2002-03-08 WO PCT/EP2002/003240 patent/WO2003076416A1/en not_active Application Discontinuation
- 2002-03-08 AU AU2002249275A patent/AU2002249275A1/en not_active Abandoned
-
2003
- 2003-03-04 SV SV2003001495A patent/SV2003001495A/en not_active Application Discontinuation
- 2003-03-06 UY UY27700A patent/UY27700A1/en not_active Application Discontinuation
- 2003-03-06 MX MXPA04008681A patent/MXPA04008681A/en unknown
- 2003-03-06 BR BR0308280-6A patent/BR0308280A/en not_active IP Right Cessation
- 2003-03-06 AP APAP/P/2004/003125A patent/AP2004003125A0/en unknown
- 2003-03-06 PL PL03372622A patent/PL372622A1/en not_active Application Discontinuation
- 2003-03-06 CN CNA038048752A patent/CN1738806A/en active Pending
- 2003-03-06 AU AU2003212307A patent/AU2003212307A1/en not_active Abandoned
- 2003-03-06 EA EA200401053A patent/EA200401053A1/en unknown
- 2003-03-06 PE PE2003000218A patent/PE20031018A1/en not_active Application Discontinuation
- 2003-03-06 KR KR10-2004-7013994A patent/KR20040095270A/en not_active Application Discontinuation
- 2003-03-06 WO PCT/EP2003/002277 patent/WO2003076417A2/en not_active Application Discontinuation
- 2003-03-06 CA CA002478706A patent/CA2478706A1/en not_active Abandoned
- 2003-03-06 JP JP2003574636A patent/JP2005526070A/en not_active Withdrawn
- 2003-03-06 AR ARP030100749A patent/AR039562A1/en not_active Application Discontinuation
- 2003-03-06 IL IL16381803A patent/IL163818A0/en unknown
- 2003-03-06 EP EP03708181A patent/EP1492775A2/en not_active Withdrawn
- 2003-03-06 OA OA1200400234A patent/OA12782A/en unknown
- 2003-03-06 PA PA20038568501A patent/PA8568501A1/en unknown
-
2004
- 2004-08-19 IS IS7414A patent/IS7414A/en unknown
- 2004-08-25 CO CO04082792A patent/CO5601020A2/en not_active Application Discontinuation
- 2004-08-31 MA MA27842A patent/MA27183A1/en unknown
- 2004-09-03 EC EC2004005278A patent/ECSP045278A/en unknown
- 2004-09-03 TN TNP2004000169A patent/TNSN04169A1/en unknown
- 2004-09-24 NO NO20044041A patent/NO20044041L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1492775A2 (en) | 2005-01-05 |
| TNSN04169A1 (en) | 2007-03-12 |
| PA8568501A1 (en) | 2003-12-19 |
| AU2002249275A1 (en) | 2003-09-22 |
| UY27700A1 (en) | 2003-10-31 |
| AU2003212307A1 (en) | 2003-09-22 |
| BR0308280A (en) | 2004-12-28 |
| AP2004003125A0 (en) | 2004-09-30 |
| CA2478706A1 (en) | 2003-09-18 |
| EA200401053A1 (en) | 2005-04-28 |
| PL372622A1 (en) | 2005-07-25 |
| WO2003076417A3 (en) | 2003-11-13 |
| ECSP045278A (en) | 2004-10-26 |
| IS7414A (en) | 2004-08-19 |
| NO20044041L (en) | 2004-10-07 |
| MXPA04008681A (en) | 2004-12-06 |
| WO2003076416A1 (en) | 2003-09-18 |
| WO2003076417A2 (en) | 2003-09-18 |
| CO5601020A2 (en) | 2006-01-31 |
| OA12782A (en) | 2006-07-10 |
| SV2003001495A (en) | 2003-11-04 |
| JP2005526070A (en) | 2005-09-02 |
| IL163818A0 (en) | 2005-12-18 |
| PE20031018A1 (en) | 2004-01-09 |
| KR20040095270A (en) | 2004-11-12 |
| CN1738806A (en) | 2006-02-22 |
| AR039562A1 (en) | 2005-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA27183A1 (en) | OXO-AZABICYCLIC COMPOUNDS | |
| CA2481461A1 (en) | Derivatives of n-[phenyl(piperidin-2-yl) methyl] benzamide, the preparation method thereof and application of same in therapeutics | |
| MA27439A1 (en) | NOVEL SPIROCONDENSIVE QUINAZOLINONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | |
| MA26989A1 (en) | PYRIDINE DERIVATIVES MATRIX METALLOPROTEINASE INHIBITORS | |
| MA28328A1 (en) | COMBINATIONS OF ACTIVE FUNGICIDE SYNERGISTIC AGENTS | |
| HUP0203700A2 (en) | N-substituted 2-cyanopyrrolidines and their use as antidiabetic agents and pharmaceutical compositions containing them | |
| KR900012906A (en) | N-phenyl-N- (4-piperidinyl) amide useful as an analgesic | |
| MA27774A1 (en) | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | |
| MA27573A1 (en) | SINOMENIN AND SINOMENIN DERIVATIVES, SYNTHESIS AND USE. | |
| MA30014B1 (en) | SPIROCYCLIC DERIVATIVES | |
| MA30784B1 (en) | PHENYL DERIVATIVES AND THE USE THEREOF AS IMMUNOMODULATORS. | |
| EP1840125A3 (en) | Intermediates for the preparation of dioxane-2-alkyl carbamates | |
| MA31674B1 (en) | Derivatives of 7-alkynil-1,8-naviteredone prepared and therapeutic uses | |
| MA27135A1 (en) | ORAL ANTIDIABETIC AGENTS | |
| MA27712A1 (en) | TRIAZOLES USEFUL IN THERAPEUTICS | |
| FR2870541A1 (en) | ANTIGONISTIC PYRIMIDINE DERIVATIVES OF VITRONECTIN RECEPTOR | |
| MA26953A1 (en) | BRIDGE PIPERAZINE DERIVATIVES. | |
| MA27795A1 (en) | CYCLIC AMINE DERIVATIVES, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | |
| MA27492A1 (en) | NOVEL ANTAGONIST DERIVATIVES OF THE VITRONECTIN RECEPTOR, THEIR PREPARATION PROCESS, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| MA57000B1 (en) | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | |
| CA2489723A1 (en) | Novel aryl-{4-halo-4-[heteroaryl-methylamino)-methyl]-piperidin-1-yl}-methanone derivatives, methods for production and use thereof as medicaments | |
| MA27260A1 (en) | New 3- (4-oxo-4H-chromen-2-yl) - (1H) -quinoline-4-ones derivatives, process for their preparation and pharmaceutical compositions containing them | |
| MA27545A1 (en) | New fluorinated benzothiadiazine derivatives, process for their preparation and pharmaceutical compositions containing them | |
| CA2231025A1 (en) | Novel compounds of 2-aminoindane, process for their preparation and pharmaceutical compositions containing them | |
| MA27947A1 (en) | 2-SUBSTITUTED PYRIMIDINES |